Annonce • Aug 13
Syncom Formulations (India) Limited announces Annual dividend, payable on October 30, 2026 Syncom Formulations (India) Limited announced Annual dividend of INR 0.1000 per share payable on October 30, 2026, ex-date on September 23, 2026 and record date on September 23, 2026. Valuation Update With 7 Day Price Move • Aug 13
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹15.24, the stock trades at a trailing P/E ratio of 18.7x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 81% over the past three years. Annonce • Aug 12
Syncom Formulations (India) Limited, Annual General Meeting, Sep 30, 2026 Syncom Formulations (India) Limited, Annual General Meeting, Sep 30, 2026, at 14:00 Indian Standard Time. Reported Earnings • Aug 12
First quarter 2027 earnings released: EPS: ₹0.26 (vs ₹0.21 in 1Q 2026) First quarter 2027 results: EPS: ₹0.26 (up from ₹0.21 in 1Q 2026). Revenue: ₹1.32b (up 13% from 1Q 2026). Net income: ₹245.9m (up 56% from 1Q 2026). Profit margin: 19% (up from 14% in 1Q 2026). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth. Annonce • Aug 06
Syncom Formulations (India) Limited to Report Q1, 2027 Results on Aug 11, 2026 Syncom Formulations (India) Limited announced that they will report Q1, 2027 results on Aug 11, 2026 Reported Earnings • May 23
Full year 2026 earnings released: EPS: ₹0.81 (vs ₹0.53 in FY 2025) Full year 2026 results: EPS: ₹0.81 (up from ₹0.53 in FY 2025). Revenue: ₹5.21b (up 12% from FY 2025). Net income: ₹764.4m (up 55% from FY 2025). Profit margin: 15% (up from 11% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹12.25, the stock trades at a trailing P/E ratio of 16.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 88% over the past three years. Reported Earnings • Feb 14
Third quarter 2026 earnings released: EPS: ₹0.23 (vs ₹0.14 in 3Q 2025) Third quarter 2026 results: EPS: ₹0.23 (up from ₹0.14 in 3Q 2025). Revenue: ₹1.21b (down 5.4% from 3Q 2025). Net income: ₹189.1m (up 45% from 3Q 2025). Profit margin: 16% (up from 10% in 3Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth. Reported Earnings • Nov 13
Second quarter 2026 earnings released: EPS: ₹0.18 (vs ₹0.16 in 2Q 2025) Second quarter 2026 results: EPS: ₹0.18 (up from ₹0.16 in 2Q 2025). Revenue: ₹1.27b (up 24% from 2Q 2025). Net income: ₹166.0m (up 49% from 2Q 2025). Profit margin: 13% (up from 11% in 2Q 2025). The increase in margin was driven by higher revenue. Annonce • Oct 01
Syncom Formulations (India) Limited Approves Appointment of Shri Ankit Kedarmal as Executive Chairman Syncom Formulations (India) Limited at its AGM held on September 29, 2025, approved appointment of Shri Ankit Kedarmal as Executive Chairman and to approve the remuneration payable to him. Annonce • Aug 11
Syncom Formulations (India) Limited, Annual General Meeting, Sep 29, 2025 Syncom Formulations (India) Limited, Annual General Meeting, Sep 29, 2025, at 14:00 Indian Standard Time. Reported Earnings • Aug 09
First quarter 2026 earnings released: EPS: ₹0.21 (vs ₹0.11 in 1Q 2025) First quarter 2026 results: EPS: ₹0.21 (up from ₹0.11 in 1Q 2025). Revenue: ₹1.23b (up 41% from 1Q 2025). Net income: ₹157.5m (up 106% from 1Q 2025). Profit margin: 13% (up from 8.7% in 1Q 2025). The increase in margin was driven by higher revenue. Annonce • Aug 02
Syncom Formulations (India) Limited to Report Q1, 2026 Results on Aug 08, 2025 Syncom Formulations (India) Limited announced that they will report Q1, 2026 results on Aug 08, 2025 New Risk • May 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Reported Earnings • May 21
Full year 2025 earnings released: EPS: ₹0.57 (vs ₹0.27 in FY 2024) Full year 2025 results: EPS: ₹0.57 (up from ₹0.27 in FY 2024). Revenue: ₹4.82b (up 83% from FY 2024). Net income: ₹494.3m (up 95% from FY 2024). Profit margin: 10% (in line with FY 2024). Valuation Update With 7 Day Price Move • May 16
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹17.49, the stock trades at a trailing P/E ratio of 42x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 31% over the past year. Annonce • May 13
Syncom Formulations (India) Limited to Report Q4, 2025 Results on May 19, 2025 Syncom Formulations (India) Limited announced that they will report Q4, 2025 results on May 19, 2025 Valuation Update With 7 Day Price Move • Mar 24
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹18.24, the stock trades at a trailing P/E ratio of 43.8x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 53% over the past year. Valuation Update With 7 Day Price Move • Mar 10
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹17.11, the stock trades at a trailing P/E ratio of 41.1x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 29% over the past year. Reported Earnings • Feb 11
Third quarter 2025 earnings released: EPS: ₹0.14 (vs ₹0.09 in 3Q 2024) Third quarter 2025 results: EPS: ₹0.14 (up from ₹0.09 in 3Q 2024). Revenue: ₹1.32b (up 102% from 3Q 2024). Net income: ₹130.0m (up 86% from 3Q 2024). Profit margin: 9.9% (in line with 3Q 2024). Annonce • Feb 03
Syncom Formulations (India) Limited to Report Q3, 2025 Results on Feb 12, 2025 Syncom Formulations (India) Limited announced that they will report Q3, 2025 results on Feb 12, 2025 Reported Earnings • Nov 12
Second quarter 2025 earnings released: EPS: ₹0.16 (vs ₹0.08 in 2Q 2024) Second quarter 2025 results: EPS: ₹0.16 (up from ₹0.08 in 2Q 2024). Revenue: ₹1.06b (up 67% from 2Q 2024). Net income: ₹111.1m (up 71% from 2Q 2024). Profit margin: 10% (in line with 2Q 2024). Annonce • Nov 05
Syncom Formulations (India) Limited to Report Q2, 2025 Results on Nov 11, 2024 Syncom Formulations (India) Limited announced that they will report Q2, 2025 results on Nov 11, 2024 Valuation Update With 7 Day Price Move • Sep 19
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹22.28, the stock trades at a trailing P/E ratio of 73.2x. Average trailing P/E is 42x in the Pharmaceuticals industry in India. Total returns to shareholders of 162% over the past year. New Risk • Sep 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Aug 21
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₹19.07, the stock trades at a trailing P/E ratio of 62.9x. Average trailing P/E is 37x in the Pharmaceuticals industry in India. Total returns to shareholders of 112% over the past year. Annonce • Aug 13
Syncom Formulations (India) Limited, Annual General Meeting, Sep 30, 2024 Syncom Formulations (India) Limited, Annual General Meeting, Sep 30, 2024, at 14:00 Indian Standard Time. Reported Earnings • Aug 13
First quarter 2025 earnings released: EPS: ₹0.11 (vs ₹0.07 in 1Q 2024) First quarter 2025 results: EPS: ₹0.11 (up from ₹0.07 in 1Q 2024). Revenue: ₹885.9m (up 48% from 1Q 2024). Net income: ₹76.3m (up 74% from 1Q 2024). Profit margin: 8.6% (up from 7.3% in 1Q 2024). The increase in margin was driven by higher revenue. Annonce • Aug 02
Syncom Formulations (India) Limited to Report Q1, 2025 Results on Aug 12, 2024 Syncom Formulations (India) Limited announced that they will report Q1, 2025 results on Aug 12, 2024 Valuation Update With 7 Day Price Move • Jul 15
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹16.01, the stock trades at a trailing P/E ratio of 59.5x. Average trailing P/E is 35x in the Pharmaceuticals industry in India. Total returns to shareholders of 112% over the past year. Reported Earnings • May 19
Full year 2024 earnings released: EPS: ₹0.34 (vs ₹0.22 in FY 2023) Full year 2024 results: EPS: ₹0.34 (up from ₹0.22 in FY 2023). Revenue: ₹2.77b (up 24% from FY 2023). Net income: ₹253.1m (up 26% from FY 2023). Profit margin: 9.1% (up from 8.9% in FY 2023). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Apr 03
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹12.85, the stock trades at a trailing P/E ratio of 46x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 96% over the past year. Annonce • Mar 29
Syncom Formulations (India) Limited Announces Board Changes Syncom Formulations (India) Limited announced that tenure completion of Shri Vinod Kumar Kabra, Shri Krishna Das Neema and Shri Praveen Jindal Independent Director(s) of the Company appointed w.e.f., 1 April, 2014 for a tenure of five (5) year and further were re-appointed w.e.f. 1 April, 2019 for further tenure of five (5) year in the category of Non-Executive Independent Directors of the company w.e.f. close of working hour of 31 March, 2024. Reported Earnings • Feb 15
Third quarter 2024 earnings released: EPS: ₹0.09 (vs ₹0.06 in 3Q 2023) Third quarter 2024 results: EPS: ₹0.09 (up from ₹0.06 in 3Q 2023). Revenue: ₹696.9m (up 22% from 3Q 2023). Net income: ₹70.0m (up 69% from 3Q 2023). Profit margin: 10.0% (up from 7.2% in 3Q 2023). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Dec 26
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹14.15, the stock trades at a trailing P/E ratio of 56.5x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 55% over the past year. Valuation Update With 7 Day Price Move • Nov 23
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to ₹12.65, the stock trades at a trailing P/E ratio of 50.6x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 62% over the past year. Reported Earnings • Nov 11
Second quarter 2024 earnings released: EPS: ₹0.08 (vs ₹0.06 in 2Q 2023) Second quarter 2024 results: EPS: ₹0.08 (up from ₹0.06 in 2Q 2023). Revenue: ₹678.4m (up 25% from 2Q 2023). Net income: ₹65.1m (up 81% from 2Q 2023). Profit margin: 9.6% (up from 6.6% in 2Q 2023). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Nov 09
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to ₹10.30, the stock trades at a trailing P/E ratio of 47x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Annonce • Aug 15
Syncom Formulations (India) Limited, Annual General Meeting, Sep 26, 2023 Syncom Formulations (India) Limited, Annual General Meeting, Sep 26, 2023, at 15:00 Indian Standard Time. Reported Earnings • Aug 15
First quarter 2024 earnings released First quarter 2024 results: EPS: ₹0.07. Revenue: ₹617.1m (up 20% from 1Q 2023). Net income: ₹44.0m (up 14% from 1Q 2023). Profit margin: 7.1% (down from 7.5% in 1Q 2023). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • Aug 07
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹9.25, the stock trades at a trailing P/E ratio of 43.4x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Annonce • Aug 04
Syncom Formulations (India) Limited to Report Q1, 2024 Results on Aug 14, 2023 Syncom Formulations (India) Limited announced that they will report Q1, 2024 results on Aug 14, 2023 Reported Earnings • Jun 02
Full year 2023 earnings released: EPS: ₹0.24 (vs ₹0.24 in FY 2022) Full year 2023 results: EPS: ₹0.24. Revenue: ₹2.39b (up 8.7% from FY 2022). Net income: ₹200.7m (up 1.4% from FY 2022). Profit margin: 8.4% (down from 9.0% in FY 2022). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • Mar 28
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹5.00, the stock trades at a trailing P/E ratio of 28.7x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Reported Earnings • Feb 14
Third quarter 2023 earnings released: EPS: ₹0.06 (vs ₹0.07 in 3Q 2022) Third quarter 2023 results: EPS: ₹0.06. Revenue: ₹593.6m (up 3.7% from 3Q 2022). Net income: ₹41.4m (up 3.3% from 3Q 2022). Profit margin: 7.0% (in line with 3Q 2022). Annonce • Feb 02
Syncom Formulations (India) Limited to Report Q3, 2023 Results on Feb 13, 2023 Syncom Formulations (India) Limited announced that they will report Q3, 2023 results on Feb 13, 2023 Valuation Update With 7 Day Price Move • Dec 23
Investor sentiment improved over the past week After last week's 24% share price gain to ₹9.70, the stock trades at a trailing P/E ratio of 56.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Board Change • Nov 21
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. No experienced directors. 6 highly experienced directors. Additional Non-Executive Independent Woman Director Ruchi Jindal was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.